Investigation of an mpox outbreak affecting many vaccinated persons in Chicago, IL—March 2023–June 2023
Emily A G Faherty,Taylor Holly,Yasmin P Ogale,Hillary Spencer,Ashley M Becht,Gordon Crisler,Michael Wasz,Patrick Stonehouse,Hannah J Barbian,Christy Zelinski,Alyse Kittner,Dorothy Foulkes,Kendall W Anderson,Tiffany Evans,Lavinia Nicolae,Amber Staton,Carla Hardnett,Michael B Townsend,William C Carson,S Satheshkumar Panayampalli,Christina L Hutson,Crystal M Gigante,Laura A S Quilter,Susan Gorman,Brian Borah,Stephanie R Black,Massimo Pacilli,David Kern,Janna Kerins,Andrea M McCollum,Agam K Rao,Irina Tabidze
DOI: https://doi.org/10.1093/cid/ciae181
IF: 20.999
2024-04-04
Clinical Infectious Diseases
Abstract:Background After months of few mpox cases, an increased number of cases were reported in Chicago during May 2023; predominantly among fully vaccinated patients. We investigated the outbreak scope, differences between vaccinated and unvaccinated patients, and hypotheses for monkeypox virus (MPXV) infection after vaccination. Methods We interviewed patients and reviewed medical records to assess demographic, behavioral, and clinical characteristics, mpox vaccine status, and vaccine administration routes. We evaluated serum antibody levels after infection and compared patient viral genomes with MPXV sequences in available databases. We discussed potential vaccine compromise with partners who manufactured, handled, and administered vaccine associated with breakthrough infections. Results During March 18–June 27, 2023, we identified 49 mpox cases; 57% of these mpox patients were fully vaccinated (FV). FV patients received both JYNNEOS doses subcutaneously (57%), intradermally (7%), or via heterologous administration (36%). FV patients had more median sex partners (3, IQR=1-4) versus not fully vaccinated (NFV) patients (1, IQR=1-2). Thirty-six of 37 sequenced specimens belonged to lineage B.1.20 of clade IIb MPXV, which did not demonstrate any amino acid changes relative to B.1, the predominant lineage from May 2022. Vaccinated patients demonstrated expected humoral antibody responses; none were hospitalized. No vaccine storage excursions were identified. Approximately 63% of people at risk for mpox in Chicago were FV during this period. Conclusions Our investigation indicated cases were likely due to frequent behaviors associated with mpox transmission, even with relatively high vaccine effectiveness and vaccine coverage. Cases after vaccination might occur in similar populations.
immunology,infectious diseases,microbiology